Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial

Background Plasma levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) are increased in patients with chronic heart failure (CHF). Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis. Objectives To assess t...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2007-08, Vol.9 (8), p.795-801
Main Authors: Olsson, Lars G., Swedberg, Karl, Cleland, John G.F., Spark, Phillip A., Komajda, Michel, Metra, Marco, Torp-Pedersen, Christian, Remme, Willem J., Scherhag, Armin, Poole-Wilson, Philip
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Aged
Carbazoles - therapeutic use
Chronic Disease
chronic heart failure
Female
Heart Failure - blood
Heart Failure - drug therapy
Heart Failure - mortality
Humans
Male
Metoprolol - therapeutic use
Middle Aged
Natriuretic Peptide, Brain - blood
natriuretic peptides
Peptide Fragments - blood
Prognosis
Propanolamines - therapeutic use
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Plasma levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) are increased in patients with chronic heart failure (CHF). Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis. Objectives To assess the prognostic importance of NT-pro BNP at baseline and during follow-up, in patients in whom beta-blocker therapy is initiated. Methods In COMET, 3029 patients with CHF in NYHA class II-IV and EF
ISSN:1388-9842
1879-0844
DOI:10.1016/j.ejheart.2007.07.010